GlassScriptPhysician profile
Melchor C Gochioco
NPI 1386654788
$11,336.20
in general payments reported to CMS, 2019-2025
31 companies · $2,429 in 2025
The $2,429 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,725 · 2022: $2,253 · 2023: $2,383 · 2024: $1,545 · 2025: $2,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,357.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,633.44 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,356.66 | 2021-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $1,174.68 | 2021 | |
| Abbott Laboratories | $1,154.23 | 2021-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Lilly USA, LLC | $776.73 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $715.63 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $556.34 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $442.65 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Intra-Sana Laboratories | $386.43 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Pharmaceuticals, INC | $355.36 | 2021-2022 | |
| Abbvie INC. | $341.82 | 2021-2024 | |
| Novo Nordisk INC | $297.72 | 2023-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $280.55 | 2022-2025 | Injectafer |
| Lucid Diagnostics INC. | $213.02 | 2022-2024 | |
| Dexcom, INC. | $206.01 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $139.30 | 2023 | Quviviq |
| Nevro Corp. | $138.29 | 2023 | Senza |
| Astellas Pharma US INC | $125.00 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $123.55 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $121.95 | 2021 | |
| Alexion Pharmaceuticals, INC. | $120.06 | 2023 | |
| Boston Scientific Corporation | $119.76 | 2021-2024 | |
| Gilead Sciences, INC. | $118.77 | 2022 | |
| Axsome Therapeutics, INC. | $112.48 | 2025 | Symbravo |
| Emd Serono, INC. | $99.98 | 2021 | |
| Horizon Therapeutics Plc | $93.71 | 2023 | Krystexxa |
| Medline Industries LP | $42.69 | 2021 | |
| Merck Sharp & Dohme LLC | $35.77 | 2021 | |
| Genentech USA, INC. | $22.12 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.00 | 2025 | |
| Exact Sciences Corporation | $15.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melchor Gochioco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.